Vancouver, British Columbia, Canada
uBriGene Biosciences Inc. has established the integrated innovative CGT CDMO platforms that provide GMP-grade plasmid and T cell production services for large-scale CAR-T productions. We provide viral vectors, including adenovirus and lentivirus vectors to meet the demands of research and/or manufacturing applications. We are committed to driving innovation and accelerating cell and gene therapy development from target to market. With its fermentation capacity ranging from 5L to 500L, uBriGene offers a versatile selection of research grade, GMP-ready or GMP grade plasmids for research and clinical applications respectively. Our two-step purification technology allows fast and cost-effective cell harvesting process. uBriGene currently operates two state-of-the-art GMP facilities, including 21 clean suites with a total area of over 133,000 sq ft, and has produced 65 batches of GMP plasmids as of 2021. Since its founding, uBriGene has been providing one-stop service to fulfill comprehensive objectives of our clients, including some of the most cutting-edge leaders of the cell and gene therapy industry. We ensure the highest quality of products and services while striving to optimize for time and cost efficiency.
No key contacts have been added to this profile yet.
No reviews have been added to this profile yet.
This is the company profile page for uBriGene on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
